MANNKIND CORP

MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases. The company develops and commercializes treatments for unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease, with expertise in drug-device combinations. Its cardiometabolic business currently includes three commercial products: Afrezza (insulin human) Inhalation Powder, Furoscix (furosemide injection), and the V-Go wearable insulin delivery device. Afrezza is an ultra rapid-acting inhaled insulin for adults with diabetes, developed by MannKind. It is a dry powder formulation of human insulin delivered via a portable inhaler at the start of a meal, dissolving rapidly in the lung for quick bloodstream delivery. Furoscix, acquired in October 2025 from scPharmaceuticals Inc., is a novel furosemide formulation. It delivers an 80 mg dose via an on-body infusor over five hours and is indicated for treating edema in pediatric patients weighing at least 43 kg and adults with chronic heart failure or chronic kidney disease. It is the first FDA-approved subcutaneous loop diuretic providing intravenous-equivalent diuresis at home. V-Go is a mechanical basal-bolus insulin delivery system worn like a patch, eliminating the need for multiple daily injections. It administers a continuous preset basal insulin rate over 24 hours and offers discreet on-demand bolus dosing at mealtimes. V-Go received 510(k) clearance from the FDA in 2010 and has been commercially available since 2012.